Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets

Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target

(2012) B. Sitohy et al.   CANCER RESEARCH

Tumor-Surrogate Blood Vessel Subtypes Exhibit Differential Susceptibility to Anti-VEGF Therapy

(2011) B. Sitohy et al.   CANCER RESEARCH

Bevacizumab Treatment for Solid Tumors

(2011) Daniel F. Hayes   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

(2011) Peter Carmeliet et al.   NATURE REVIEWS DRUG DISCOVERY

Heterogeneity of the Tumor Vasculature

(2010) Janice Nagy et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Rapamycin Inhibition of the Akt/mTOR Pathway Blocks Select Stages of VEGF-A 164 –Driven Angiogenesis, in Part by Blocking S6Kinase

(2009) Qi Xue et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

VEGF-A Induces Angiogenesis by Perturbing the Cathepsin-Cysteine Protease Inhibitor Balance in Venules, Causing Basement Membrane Degradation and Mother Vessel Formation

(2009) S.-H. Chang et al.   CANCER RESEARCH